Analysis of the discontinuation of protease inhibitor therapy in routine clinical practice

Scandinavian Journal of Infectious Diseases

Volumn 31, Issue 5, 1999, Pages 495-499

  Ferrer, Elena ^a   Consiglio, Ezequiel ^a   Podzamczer, Daniel ^a,b   Grau, Imma ^a   Ramon, Jose Maria ^a   Perez, Jose Luis ^a   Gudiol, Francesc ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Ciutat Sanitaria de Bellvitge   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL PRACTICE; DISEASE COURSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PATIENT COUNSELING; PHYSICIAN; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANALYSIS OF VARIANCE; COHORT STUDIES; COUNSELING; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; MALE; PHYSICIAN'S PRACTICE PATTERNS; PROSPECTIVE STUDIES; RITONAVIR; SAQUINAVIR; TREATMENT REFUSAL; VIRAL LOAD;

EID: 0032701801     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365549950164030     Document Type: Article

References (30)

1. Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimetre. N Engl J Med 1996; 335: 1081-90.
2. Hughes MD, Johnson VA, Hirsch MS, Bremer JW, Elbeik T, Erice A, et al. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. Ann Intern Med 1997; 126: 929-38.
3. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-60.
4. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998; 352: 1725-30.
5. Decks SG, Smith M, Holodniy M, Kahn J. HIV-1 protease inhibitors: a review for clinicians. JAMA 1997; 277: 145-53.
6. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-8.
7. Kumar GN, Rodrigues AD, Buko AM, Denissen JF. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996; 277: 423-31.
8. Mehta S, Moore RD, Graham NMH. Potential factors affecting adherence with HIV therapy. AIDS 1997; 11: 1665-70.
9. Rhone SA, Hogg RS, Yip B, Sherlock Ch, Conway B, Schlechter MT, et al. The antiviral effect of ritonavir and saquinavir in combination amongst HIV-infected adults: results from a community-based study. AIDS 1998; 12: 619-24.
10. Fätkenheuer G, Theisen A, Rockstroh J, Grabow T, Wicke Ch, Becker K, et al. Virologic treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997; 11: F113-6.
11. Mocroft A, Gill MJ, Davidson W, Philips AN. Predictors of a viral response and subsequent virological failure in patients with HIV starting a protease inhibitor. AIDS 1998; 12: 2161-7.
12. Wit FWNM, van Leeuwen R, Weverling GJ, Jurriaans S, Nauta K, Steingrover R, et al. Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. J Infect Dis 1999; 179: 790-8.
13. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999; 353: 863-8.
14. O'Brien WA, Hartigan PM, Daar ES, Simberkoff MS, Hamilton JD, VA Cooperative Study Group on AIDS. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. Ann Intern Med 1997; 126: 939-45.
15. Samet JH, Libman H, Steger KA, Dhawan RK, Chen J, Shevitz AH, et al. Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. Am J Med 1992; 92: 495-502.
16. Singh N, Squier C, Hayes P, Wagener MM, Sivek C, Goetz A, et al. Determinants of compliance in patients with HIV: prospective assessment with implications for enhancing compliance. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, October 1994, Abstract I-170.
17. Tebas P, Royal M, Fichtenbaum C, Blutman J, Arens M, Horgan M, et al. Relationship between adherence to HAART and disease state. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998, Abstract 149.
18. Hecht FM, Colfax G, Swanson M, Chesney MA. Adherence and effectiveness of protease inhibitors in clinical practice. 5th Conference on Retrovirus and Opportunistic Infections. Chicago, February 1998, Abstract 151.
19. Shelton MJ, Esch LD, Hewitt RG, Cousins S, Morse GD. The impact of patient-reported adherence with antiretroviral therpay on virologic response. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, September 1998, Abstract I-170.
20. Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, et al. A short-term study of the safety, pharmacokinetics and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995; 333: 1528-33.
21. Merry C, Barry MG, Mulcahy F, Ryan M, Heavey J, Tija FJ, et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997; 11: F29-33.
22. Carpenter CCJ, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in . Updated recommendations of the International AIDS Society-USA panel. JAMA 1998; 280: 78-86.
23. Bangsberg D, Tulsky JP, Hecht FM, Moss AR. Protease inhibitors in the homeless. JAMA 1997; 278: 63-5.
24. th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, September 1998, Abstract I-177.
25. Burger DM, Hugen PWH, Prins JM, Van de Ende ME, Reiss P, Lange JMA. Pharmacokinetics of an Indinavir/Ritonavir 800/100 mg BID regimen. 6th Conference on Retroviruses and Opportunistic Infections; Chicago: January 31 February 4, 1999, Abstract 363.
26. Johnson M, Petersen A, Winslade J, Clendeninn N. Comparison of bid and tid dosing of viracept in combination with stavudine and lamivudine. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998, Abstract 373.
27. Montaner JSG, Reiss P, Cooper D, Vella S, Harris M, Conway B, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial. JAMA 1998; 279: 930-7.
28. Katlama C, Murphy R, Johnson V, Squires K, Horban A, Gatell J, et al. The Atlantic Study: A randomized open-label study comparing two protease inhibitors-sparing antiretroviral strategies vs. a standard PI-containing regimen. 6th Conference on Retroviruses and Opportunistic Infections; Chicago: January 31 February 4, 1999, Abstract 18.
29. Morales-Ramirez J, Tashima K, Hardy D, Johnson P, Nelson M, Staszewski S, et al. A phase II, multi-center randomized, open label study to compare the antiretroviral activity and tolerability of efavirenz (EFV) + indinavir (IDV), versus EFV + zidovudine (ZDV) + Lamivudine (3TC), versus IDV + 3TC at > 36 weeks [DMP 266-006]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, September 1998, Abstract I-103.
30. Havlir D, Mc Laughlin MM, Richman DD. A pilot study to evaluate the development of resistance to nevirapine in asymptomatic human immunodeficiency virus-infected patients with CD4 cell counts of > 500/mm3. AIDS Clinical Trials Group Protocol 208. J Infect Dis 1995; 172: 1379-83.